

Applicants: Carlos Cordon-Cardo et al.
Serial No.: 10/009,861
Filed: December 10, 2001
Page 2

In the claims:

Please replace the claims with the listing of claims below.

1. - 18. (cancelled)

19. (currently amended) A method for treating a subject afflicted with androgen-independent prostate cancer in a subject, wherein the prostate cancer is characterized by overexpression of prostate cancer cells which overexpress Her-2/neu protein, comprising which method comprises administering to the subject therapeutically effective amounts of (i) a therapeutically effective amount of a humanized monoclonal antibody which specifically selectively binds to an extracellular domain of the Her-2/neu protein [[and]] in conjunction with (ii) a therapeutically effective amount of an antitumor chemotherapeutic agent, wherein treatment with the monoclonal antibody and the chemotherapeutic agent inhibits prostate cancer cell growth more than treatment with either the monoclonal antibody alone or the chemotherapeutic agent alone, so as to thereby treat the subject afflicted with androgen-independent prostate cancer in the subject.

20. - 27. (cancelled)

28. (previously presented) The method of claim 19, wherein the antitumor chemotherapeutic agent is selected from the group consisting of paclitaxel, doxorubicin, cis-platin, cyclophosphamide, etoposide, vinorelbine, vinblastine, tamoxifen, colchicine, and 2-methoxyestradiol.

Applicants: Carlos Cordon-Cardo et al.
Serial No.: 10/009,861
Filed: December 10, 2001
Page 3

29. - 30. (cancelled)